NGMS stock holds its ground after Neogenomics revenue trends improve

Neogenomics, Inc. (ISIN US64049M2098) reported $169.0 million in 2024 revenue and $58.4 million in fourth-quarter revenue, while NGMS stock closed at a market value of roughly $1.1 billion as of the latest available company profile data. The company also said full-year 2024 adjusted EBITDA reached a loss of $3.9 million, improving from a loss of $25.8 million in 2023.

Revenue up 12.5%

The top-line comparison is the most useful data point for investors. Neogenomics' 2024 revenue of $169.0 million was up 12.5% from $150.3 million in 2023, and fourth-quarter revenue of $58.4 million gave the business a stronger starting point into 2025.

That same period also showed tighter operating discipline. Adjusted EBITDA improved to a $3.9 million loss in 2024 from a $25.8 million loss in 2023, a year-over-year swing of $21.9 million.

Margin recovery matters

The improvement in adjusted EBITDA suggests the company is gaining more leverage from volume and cost control. For a diagnostics group, that matters as much as revenue growth because laboratory fixed costs can weigh on profitability when utilization is weak.

The latest available market-capitalization reference for NGMS stock puts the equity at about $1.1 billion, which helps frame the scale of the recovery story. The market is still pricing a mid-cap diagnostics platform rather than a mature, high-margin healthcare services business.

Diagnostic testing remains the core

Neogenomics' main business is cancer-focused genetic and molecular testing, which remains the revenue engine behind the 2024 improvement. The company continues to rely on clinical testing volume, reimbursement quality, and operating efficiency to move from revenue growth toward sustained profitability.

That mix makes the 2024 figures more important than a simple headline revenue print. Revenue growth of 12.5% is useful, but the smaller adjusted EBITDA loss is the clearest sign that the business model is moving in the right direction.

Market value and scale

The company traded with a market value of about $1.1 billion in the latest available profile data, which is modest for a national diagnostics operator. That scale helps explain why each incremental improvement in margin can matter more to valuation than a small change in revenue alone.

For NGMS stock, the relevant comparison is not just last quarter versus the one before it. It is the full-year swing from a $25.8 million adjusted EBITDA loss in 2023 to a $3.9 million loss in 2024, alongside $169.0 million in annual revenue.

Genetic testing focus

The company's testing platform centers on oncology diagnostics, including molecular and genetic assays used by clinicians for treatment decisions. That product mix gives Neogenomics exposure to a recurring clinical workflow rather than a one-off device sale.

At this stage, the business case is still built on execution: higher test volume, better reimbursement, and narrower losses. The 2024 numbers show progress on all three fronts, even if the company has not yet reached full adjusted profitability.

Latest valuation snapshot

NGMS stock is best read through the revenue and EBITDA trend rather than a single-day price move. The latest available market-cap figure of about $1.1 billion, combined with $169.0 million in 2024 revenue and a $3.9 million adjusted EBITDA loss, defines the current scale of the story.